105512-81-0

Basic information

• Product Name: 4-(3-BROMO-PHENYL)-THIAZOL-2-YLAMINE
• Synonyms: BUTTPARK 41\03-41;AURORA 22596;ART-CHEM-BB B000319;4-(3-BROMO-PHENYL)-THIAZOL-2-YLAMINE;4-(3-BROMOPHENYL)-1,3-THIAZOL-2-AMINE;4-(3-BROMOPHENYL)-1,3-THIAZOLE-2-YLAMINE;AKOS B000319;AKOS BBS-00008008
• CAS NO: 105512-81-0
• Molecular Formula: C₉H₇BrN₂S
• Molecular Weight: 255.13
• Mol File: 105512-81-0.mol

Chemical Properties

• Melting Point: 130-131°C
• Boiling Point: 398.8 °C at 760 mmHg
• Flash Point: 195 °C
• Appearance: /
• Density: 1.636
• Vapor Pressure: 1.43E-06mmHg at 25°C
• Refractive Index: 1.684
• PKA: 4.14±0.10(Predicted)
• CAS DataBase Reference: 4-(3-BROMO-PHENYL)-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMO-PHENYL)-THIAZOL-2-YLAMINE(105512-81-0)
• EPA Substance Registry System: 4-(3-BROMO-PHENYL)-THIAZOL-2-YLAMINE(105512-81-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 105512-81-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Bromo-phenyl)-thiazol-2-ylamine is used as a chemical intermediate for the synthesis of more complex pharmaceutical compounds. Its versatile chemistry and presence of functional groups make it a promising candidate for the development of new drugs with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, 4-(3-Bromo-phenyl)-thiazol-2-ylamine may be utilized in the development of novel materials with specific properties. 4-(3-BROMO-PHENYL)-THIAZOL-2-YLAMINE's unique structure and reactivity could contribute to the creation of advanced materials with applications in various industries.

InChI:InChI=1/C9H7BrN2S/c10-7-3-1-2-6(4-7)8-5-13-9(11)12-8/h1-5H,(H2,11,12)

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 17356-08-0 thiourea 
• 18523-22-3 2,3'-dibromoacetophenone 
• 1314243-08-7 1-(1-azidovinyl)-3-bromobenzene 
• 333-20-0 potassium thioacyanate 
• 1147550-11-5 ammonium thiocyanate 
• 2039-86-3 3-bromostyrene 
• 2725-82-8 1-bromo-3-ethylbenzene 
• 109347-40-2 2-(3-bromophenyl)acetaldehyde 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 446858-96-4 N-(4-(3-bromophenyl)thiazol-2-yl)-2-chloroacetamide 
• 30216-50-3 4-(3-bromophenyl)thiazole 
• 900514-78-5 4-biphenyl-3-ylthiazol-2-ylamine trifluoroacetic acid salt 

Relevant articles and documents

Chemical synthesis, molecular modeling and pharmacophore mapping of new pyrrole derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth

Abstract: Substituted phenylthiazolyl benzamide and pyrrolyl benzamide derivatives were developed using molecular hybridization technique to create novel lead antimycobacterial molecules used to fight against Mycobacteriumtuberculosis. The newly synthesized molecules have inhibited InhA, the enoyl-ACP reductase enzyme from the mycobacterial type II fatty acid biosynthetic pathway. Of these, compound 3b showed H-bonding interactions with Tyr158 and co-factor NAD+ that binds the active site of InhA. All the molecules were screened for in vitro antitubercular activity against M. tuberculosis H37Rv, as well as some representative molecules as the inhibitors of InhA. Thirteen compounds exhibited good anti-TB activities (MIC = 1.6 μg/mL), but only few representative molecules showed the moderate InhA enzyme inhibition activity. [Figure not available: see fulltext.].

Synthesis and antibacterial screening of novel 2-(4-(aryl) thiazol-2-yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione derivatives

A series of novel 2-(4-(aryl)thiazol-2-yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisoindole-1,3(2H)-dione derivatives were synthesized and evaluated for their antimicrobial activity. The structures of the synthesized derivatives (9a-j) were confirmed by means of IR, 1H-NMR, 13C-NMR and elemental analyses. All the compounds 9a-j showed activity against all microorganisms. Compounds 9a, 9c-d, and 9j exhibit potent antibacterial activity against tested S. pyogenes. Compounds 9c showed higher activity than standards against C. perfringes. 9a-e, 9j and 9i possess good activity against A. tumefacen.

Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition

A series of novel hybrid compounds of hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine with aminothiazole scaffolds were synthesized. The synthesized compounds were evaluated for their cytotoxic activity against the NCI-60 human tumor cell line panel. Compounds 7c, 7d and 7e exhibited significant antiproliferative activities at 10?5 M dose. Compound 7c exhibited excellent cytotoxic activity against CNS cancer cell lines including SNB-75 and SF-295 as well as renal cancer cell line CAKI-1 when compared with sorafenib as standard anticancer drug. In addition, compound 7d showed almost comparable anticancer activity to sorafenib against SNB-75 cell line and displayed moderate activity against SF-295 and CAKI-1 cell lines in comparison to sorafenib. Compound 7c inhibited the vascular endothelial growth factor receptor 2 (VEGFR-2) with IC50 of 62.48 ± 3.7 nM and decreased both total VEGFR-2 and phosphorylated VEGFR-2 in treated SNB-75 cells suggesting its ability to down regulate cell proliferation, growth, and survival. The flow cytometric analysis showed that 7c displayed its cytotoxic activity through the reduction of the cellular proliferation and induction of cell cycle arrest at the G2/M phase. Compound 7c clearly boosted the level of the apoptotic caspase-3. All the synthesized compounds were also screened for their antibacterial and antifungal activity against four pathogenic strains of both Gram-positive and Gram-negative as well as Candida albicans. Only compound 7d exhibited antifungal activity against Candida albicans compared to nystatin as the standard antifungal compound.

1-Methylimidazolium ionic liquid supported on Ni@zeolite-Y: fabrication and performance as a novel multi-functional nanocatalyst for one-pot synthesis of 2-aminothiazoles and 2-aryl benzimidazoles

In the present study, 1-methyl-3-(3-trimethoxysilylpropyl)-1H-imidazol-3-ium chloride-supported Ni@zeolite-Y-based nanoporous materials (Ni@zeolite-Im-IL) were synthesized and their structures were confirmed using different characterization techniques such as FT-IR, FE-SEM, EDX, XRD, BET and TGA-DTG analyses. In order to synthesize this multi-functional nano-system, zeolite-NaY was modified first, with exchanged Ni2+ ions and 3-chloropropyltriethoxysilane (CPTES) as a coupling reagent and then functionalized to imidazolium chloride ionic liquid by N-methylimidazole. New multi-functional nano-material of Ni@zeolite-Im-IL demonstrated high activity in the catalytic synthesis of 2-aminothiazoles 3a–l by one-pot reaction of methylcarbonyls, thiourea and iodine at 80?°C in DMSO with good to excellent yields (85–98%). Also, the catalytic synthesis of 2-aryl benzimidazoles, 6a–m was performed by the condensational reaction of o-arylendiamine and aromatic aldehydes in EtOH at room temperature with excellent yields (90–98%). Advantages of this efficient synthetic strategy include higher purity and shorter reaction time, excellent yield, easy isolation of products, the good stability, activity and feasible reusability of the metallic ionic liquid nanocatalyst. These benefits have made this method more compatible with the principles of green chemistry. Graphical abstract: [Figure not available: see fulltext.]

METHODS OF TREATING CANCERS

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as acute myeloid leukemia.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

METHODS OF TREATING CANCERS

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as acute myeloid leukemia. The present invention features methods to treat AML, e.g., in a subject in need thereof. In one aspect, the invention feat

Solid state thiazole-based fluorophores: Promising materials for white organic light emitting devices

A facile and more efficient solvent-free mechanochemical synthetic route has been developed for the synthesis of a series of solid state white light emissive thiazole-based donor-acceptor (D-A) type fluorophores, 2-(3-pyridyl)/2-aminothiazoles from ω-bromomethylketones and pyridine-3-carbothioamide/thiourea in the presence of silica-supported HClO4 as a reusable solid Br?nsted acid catalyst at RT. The photophysical and electrochemical properties of these compounds have been derived. Most of the studied D-A type solid thiazole-based fluorophores emitted white light and it can be tuned from warm - ideal - cold white light by introduction of a variety of substituents at 4th position of 2-(3-pyridyl)/2-aminothiazoles. Further, HOMO and LUMO energy levels of the titled compounds are found to be in the range ?5.52 eV to ?5.72 eV and ?1.84 eV to ?2.45 eV, respectively. The lifetimes of these levels of thiazole-based fluorophores have been determined through luminescence decay curves and are found to be in the range of 7.7–11 μs. The photophysical and electrochemical properties of the synthesized thiazole-based fluorophores indicate that the compounds could be promising materials for white organic light emitting devices.